News | May 04, 2026
Lilly posts explosive Q1 2026 results
Lifts full-year outlook as obesity drug boom accelerates
Lifts full-year outlook as obesity drug boom accelerates
But acquisition charges drag earnings into loss
The Danish biotech company confirmed the global study will begin in the second half of 2026
The study evaluated oral semaglutide in young patients with type 2 diabetes and found it delivered a superior reduction in HbA1c
The unit is equipped with advanced monitoring systems and supported by a multidisciplinary team
Spread across 7,000 square feet, the Bengaluru facility is positioned as a purpose-built clinical prevention centre focused on identifying silent, life-threatening diseases in asymptomatic individuals
The approved product is a generic version of Ravicti, originally developed and marketed by Horizon Therapeutics
The launch coincides with IBS Awareness Month in April
Advisory from Apollo Spectra Hospitals highlights hydration, nutrition, and screening as key preventive measures
American College of Cardiology and Korean Society of Cardiology convene global experts to address rising cardiometabolic burden
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
